SIGLEC9

Across TCGA pan-cancer cohorts, SIGLEC9 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of SIGLEC9’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SIGLEC9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SIGLEC9 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, KIRP, and THCA are the cancer types where SIGLEC9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SIGLEC9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+1.952	<.001	12	view →
KIRP	Male	All	+1.549	<.001	11	view →
THCA	Male	IV	+1.310	<.001	11	view →
HNSC	All	III,IV	+0.631	<.001	11	view →
LUAD	All	II,III,IV	−0.851	<.001	8	view →
LUSC	Female	II,III,IV	−1.541	<.001	7	view →
STAD	All	II,III,IV	+0.865	<.001	7	view →
BRCA	Female	All	+0.510	<.001	6	view →
LIHC	Male	All	−0.842	<.001	5	view →
PAAD	All	All	−1.374	.010	2	view →
READ	Female	All	−0.595	.035	1	view →
BLCA	All	IV	+0.541	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

SIGLEC9–KIRC

Open the KIRC breakdown →